PulseAugur
EN
LIVE 18:26:28
中文(ZH) 创历史新高，我国药物临床试验总量首破5000

China drug trials exceed 5,000; SK regulators eye leveraged ETFs

By PulseAugur Editorial · [1 sources] ·

China's drug clinical trial volume has surpassed 5,000, marking a new historical high according to the National Medical Products Administration's 2025 report. This includes nearly 3,000 new drug clinical trials and over 2,200 bioequivalence trials. Separately, South Korea's Financial Supervisory Service is considering measures for leveraged ETFs due to sustained retail investor demand for high-risk products, and is investigating a SpaceX IPO allocation failure by Mirae Asset. AI

RANK_REASON The cluster contains multiple unrelated news items, one about Chinese drug trials and another about South Korean financial regulation, lacking a single cohesive event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

China drug trials exceed 5,000; SK regulators eye leveraged ETFs

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Commentary
The cluster contains multiple unrelated news items, one about Chinese drug trials and another about South Korean financial regulation, lacking a single cohesive event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
96 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Setting a new historical record, China's total number of drug clinical trials exceeds 5,000 for the first time

    国家药监局今天发布2025年《中国新药注册临床试验进展年度报告》，全景式呈现我国药物临床试验的权威数据。报告显示，我国临床试验总量首次突破5000项，创历史新高。据了解，2025年《中国新药注册临床试验进展年度报告》包括新药临床试验和生物等效性试验两大类，其中，新药临床试验2997项，占为57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。（央视新闻）

RELATED ENTITIES

RELATED TOPICS